疾病知識(shí)導(dǎo)航
Lori J. Wirth, M.D.
腫瘤專(zhuān)科
專(zhuān)科認(rèn)證:內(nèi)科學(xué)、腫瘤內(nèi)科學(xué)
執(zhí)業(yè)編號(hào):205729
醫(yī)療專(zhuān)長(zhǎng):內(nèi)分泌腫瘤、甲狀腺癌、口咽癌、喉癌、鼻竇腫瘤
Lori J. Wirth博士現(xiàn)任哈佛醫(yī)學(xué)院副教授;于2008年加入麻省總醫(yī)院,任頭頸癌中心醫(yī)學(xué)主任。
Wirth博士是頭頸腫瘤領(lǐng)域的權(quán)威人士,在頭頸部癌癥的綜合治療方面頗有心得和經(jīng)驗(yàn),并為晚期甲狀腺癌提供新的治療方法。 她是負(fù)責(zé)指導(dǎo)癌癥治療和研究工作的國(guó)家和國(guó)際委員會(huì)成員。
【專(zhuān)長(zhǎng)領(lǐng)域】
頭頸部腫瘤、內(nèi)分泌腫瘤、甲狀腺癌、口咽癌、喉癌、鼻竇腫瘤
【教育背景】
1997年,畢業(yè)于哥倫比亞大學(xué)醫(yī)學(xué)院,取得醫(yī)學(xué)博士學(xué)位
2000年,于紐約長(zhǎng)老會(huì)醫(yī)院,完成住院醫(yī)培訓(xùn)
哈佛大學(xué)丹娜法伯癌癥研究院,完成血液/腫瘤專(zhuān)科培訓(xùn)
【學(xué)術(shù)著作】(摘選)
Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Thierauf J, Ramamurthy N, Jo VY, Robinson H, Frazier RP, Gonzalez J, Pacula M, Dominguez Meneses E, Nose V, Nardi V, Dias-Santagata D, Le LP, Lin DT, Faquin WC, Wirth LJ, Hess J, Iafrate AJ, Lennerz JK. Oncologist. 2019 Mar 29. pii: theoncologist.2018-0515.
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.
Clin Cancer Res. 2013 Jan 15;19(2):480-90.
Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S. Circulating BRAFLevels Correlate with Treatment in Patients with Thyroid Carcinoma. Thyroid 2018. PubMed
Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiukiewicz K, Thomas T, Nehs MA, Marqusee E, Lee SL, Janne PA, Lorch JH. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res 2018. PubMed
Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol 2017; 35:3315-3321. PubMed
Mattox A, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng Y, Chen H, Poznansky MC, Iyengar NM, Pai SI. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-L1+ TAMs. Cancer Res 2017. PubMed
Addison D, Seidelmann SB, Janjua SA, Emami H, Staziaki PV, Hallett TR, Szilveszter B, Lu MT, Cambria RP, Hoffmann U, Chan AW, Wirth LJ, Neilan TG. Human Papillomavirus Status and the Risk of Cerebrovascular Events Following Radiation Therapy for Head and Neck Cancer. J Am Heart Assoc 2017. PubMed
Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer 2017. PubMed
推薦閱讀
上市公司控股
上市公司海峽創(chuàng)新控股跨境醫(yī)療平臺(tái)
一切流程標(biāo)準(zhǔn)化
美國(guó)大型實(shí)體醫(yī)療企業(yè)
擁有美國(guó)權(quán)威醫(yī)療資源
擁有美國(guó)權(quán)威醫(yī)療轉(zhuǎn)診渠道
擁有美國(guó)官方醫(yī)療營(yíng)業(yè)執(zhí)照
國(guó)內(nèi)三甲醫(yī)院深度合作
200余家三甲醫(yī)院深度合作
落地好醫(yī)友國(guó)際醫(yī)療中心
為海外醫(yī)療患者提供出國(guó)前后醫(yī)療保障
跨境醫(yī)療行業(yè)領(lǐng)導(dǎo)者
中美遠(yuǎn)程會(huì)診市場(chǎng)占有率逾90%
出國(guó)看病獨(dú)立轉(zhuǎn)診模式嚴(yán)格控費(fèi)
符合美國(guó)HIPPA醫(yī)療法案病歷管理
聯(lián)系醫(yī)學(xué)顧問(wèn)
醫(yī)學(xué)顧問(wèn)微信在線(xiàn)